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Abstract The majority of the human genome is tran-
scribed but not translated, giving rise to noncoding RNAs
(ncRNAs), including long ncRNAs (lncRNAs, [200 nt)
that perform a wide range of functions in gene regulation.
The Fragile X mental retardation 1 (FMR1) gene is a
microsatellite locus that in the general population contains
\55 CGG repeats in its 50-untranslated region. Expansion
of this repeat region to a size of 55-200 CGG repeats,
known as premutation, is associated with Fragile X tremor
and ataxia syndrome (FXTAS). Further expansion beyond
200 CGG repeats, or full mutation, leads to FMR1 gene
silencing and results in Fragile X syndrome (FXS). Using a
novel technology called ‘‘Deep-RACE’’, which combines
rapid amplification of cDNA ends (RACE) with next
generation sequencing, we systematically interrogated the
FMR1 gene locus for the occurrence of novel lncRNAs.
We discovered two transcripts, FMR5 and FMR6. FMR5 is
a sense lncRNA transcribed upstream of the FMR1 pro-
moter, whereas FMR6 is an antisense transcript overlap-
ping the 30 region of FMR1. FMR5 was expressed in
several human brain regions from unaffected individuals
and from full and premutation patients. FMR6 was silenced
in full mutation and, unexpectedly, in premutation carriers
suggesting abnormal transcription and/or chromatin
remodeling prior to transition to the full mutation. These
lncRNAs may thus be useful as biomarkers, allowing for
early detection and therapeutic intervention in FXS and
FXTAS. Finally we show that FMR5 and FMR6 are
expressed in peripheral blood leukocytes and propose
future studies that correlate lncRNA expression with clin-
ical outcomes.
Introduction
Trinucleotide repeat expansions give rise to more than 30
neurological and neuromuscular diseases, including Hun-
tington’s disease (HD), Fragile X Syndrome (FXS) and
Spinocerebellar Ataxia (Lopez Castel et al. 2010; Mirkin
2007). FXS, an X-linked genetic disorder, is the leading
cause of inherited intellectual disability, and is otherwise
characterized by behavioral problems and specific physical
dysmorphisms. It is caused by an expansion of CGG
repeats in the 50 untranslated region (50-UTR) of the Fragile
X mental retardation 1 gene (FMR1). The 50-UTR of FMR1
contains 6–54 repeats in the general population; however,
this region occasionally expands in subsequent generations.
A size of 55–200 repeats is called a ‘‘premutation’’ (PM),
while an expansion beyond 200 repeats is called a full
mutation and results in Fragile X Syndrome in males. In
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most patients with FXS, both an upstream CpG island and
the expanded CGG/CCG repeats are hypermethylated
(Hornstra et al. 1993; Sutcliffe et al. 1992). This hyper-
methylation is associated with hypoacetylation of histones
H3 and H4 in the promoter and the 50 UTR of FMR1
(Coffee et al. 2002; Coffee et al. 1999), leading to chro-
matin condensation and transcriptional silencing. The
protein encoded by FMR1, FMRP, is an RNA-binding
protein involved in translational repression, synaptic mat-
uration, dendritic mRNA localization and nucleoplasmic
shuttling of mRNA (Antar et al. 2005; Brown et al. 1998;
Weiler et al. 1997) lending support to the idea that its
aberrant expression contributes to the intellectual disabili-
ties (ID) associated with FXS (Hinton et al. 1991; Irwin
et al. 2000; O’Donnell and Warren, 2002). FMRP may also
have other important functions in the nucleus, according to
a recent study showing that FMRP binds methylated
H3K79 chromatin and mediates the DNA-damage response
pathway (Shi et al. 2012). FMR1 premutation carriers are at
risk for developing FXTAS, a neurodegenerative condition
affecting approximately 46 % of males and 17 % of
females (Garcia-Arocena and Hagerman 2010). FXTAS is
characterized by ataxia, parkinsonism, intentional tremors,
psychiatric symptoms and cognitive decline with onset
usually after 50 years of age (Hagerman et al. 2001).
Additionally, approximately 20 % of female premutation
carriers are at an increased risk for FXPOI (Allingham-
Hawkins et al. 1999). Although each Fragile X-associated
condition does have a characteristic phenotype, great var-
iability exists in severity and penetrance.
Furthermore, the molecular mechanisms by which FXS
and FXTAS/FXPOI arise are largely unrelated. In FXS, the
symptoms are due to the silencing of FMR1 and ensuing
lack of FMRP, while in FXTAS/FXPOI the expansion does
not silence the FMR1 gene. In fact, FMRP levels in
FXTAS are not or only slightly reduced compared to the
normal population whereas FMR1 mRNA expression lev-
els are increased two to eightfold, suggesting an RNA
toxicity mechanism underlying this condition. Although
the precise mechanism for this overexpression is still
unknown, it has been postulated that a longer tract of CGG
repeats near the FMR1 promoter results in a more open
chromatin state, thereby promoting access by transcription
factors (Kenneson et al. 2001; Tassone et al. 2000).
Vast genomic regions are transcribed but not translated
and many of the resulting transcripts, known as noncoding
RNAs (ncRNAs), are enriched in the brain (Banfai et al.
2012; Cheng et al. 2005; Djebali et al. 2012). Long ncRNAs
(lncRNAs), which are ncRNAs longer than 200 nucleotides,
perform a wide range of functions, including modulation of
transcription or of the epigenetic landscape of their loci of
origin. LncRNAs can be transcribed from the sense and
antisense strands of protein-coding genes, and can arise
from introns, promoters and 30 end regions (Djebali et al.
2012; Mattick, 2005; Yan and Ma, 2012). Transcriptomic
studies have revealed that antisense transcription is a
common feature of mammalian genes that are actively
transcribed from microsatellite disease loci (Cho et al.
2005; Ladd et al. 2007; Moseley et al. 2006). Furthermore,
others and we have recently reported that lncRNAs emanate
from the FMR1 gene locus and are differentially expressed
in both FXS and premutation carriers (Khalil et al. 2008;
Ladd et al. 2007). These FMR1-derived lncRNAs are pri-
mate-specific, and animal models have not addressed their
potential influence on the FXS phenotype (The Dutch-
Belgian Fragile X Consortium 1994; Chen and Toth 2001;
Fisch et al. 1999; Godfraind et al. 1996; Miller et al. 1999;
Stafstrom et al. 2012). It is possible that ncRNAs produced
from the FMR1 locus may modulate certain aspects of FXS/
FXTAS as has been demonstrated in other human diseases
[reviewed in (Pastori and Wahlestedt 2012)]. We hypothe-
size that ncRNA may contribute to and be reflective of
clinical variability in humans and hence could be used as
biomarkers for FXS/FXTAS.
Here, we employed a recently developed method called
Deep-RACE (Olivarius et al. 2009) to comprehensively
search the entire FMR1 locus for novel lncRNAs. The
NCBI database reports several antisense-oriented ESTs
(Expressed Sequence Tags) mapping to the FMR1 locus,
suggesting the presence of as yet uncharacterized tran-
scripts. By performing rapid amplification of cDNA ends
(RACE) on total human brain RNA followed by next
generation sequencing, we have identified two new tran-
scripts that we refer to as FMR5 and FMR6. The expression
of these newly described RNA species was validated in
several regions of unaffected human brain tissue as well as
in brain samples from FXS and premutation carriers. Our
work provides a systematic analysis of the complex tran-




Here we modified an existing protocol developed in 2009
to identify in a high-throughput manner the transcription
start site of genes of interest using 50RACE (Olivarius et al.
2009). We applied the same strategy using 30RACE to
detect the end of transcripts of interest.
Sense oriented 50 RACE
50 RACE for sense-oriented novel transcripts was per-
formed using the Invitrogen 50 RACE System according to
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manufacturer instructions (Invitrogen cat#18374-058).
Briefly, strand-specific cDNA was synthesized from 1 lg
of total human brain RNA (Clontech, cat#636530) using
gene-specific primers (GSP1, Online Resource 3) located
500 bp upstream the TSS of FMR1. After first strand
cDNA synthesis, a homopolymeric tail was added to the 30-
end of the cDNA, using TdT enzyme and dCTP. Tailed
cDNA was then amplified using gene-specific primer 2
(GSP2, Online Resource 3) and the Abridged Anchor Pri-
mer (AAP) provided with the system. PCR products were
re-amplified in a nested PCR using gene-specific primer 3
(GSP3, Online Resource 3) and the abridged universal
amplification primer (AUAP) provided by the kit. The final
PCR products were submitted for next generation
sequencing.
Antisense oriented 50RACE
50 RACE for novel antisense transcripts was performed
using the 50 RACE System according to manufacturer
instructions (Invitrogen cat#18374-058). Briefly, strand-
specific cDNA was synthesized from 1 lg of total human
brain RNA (Clontech) using gene-specific primers (GSP1,
Online Resource 3) located in exon 1, exon 5 and exon 17,
thereby spanning the entire locus of interest. cDNA was
tailed with TdT enzyme and amplified using gene-specific
primer 2 (GSP2, Online Resource 3) and AAP. PCR pro-
ducts were re-amplified with gene-specific primer 3 (GSP3,
Online Resource 3) and AUAP. The final PCR products
obtained from RACE experiments in the aforementioned
regions of the locus were pooled and submitted for next
generation sequencing.
Sense oriented 30RACE
The 30RACE protocol is based on the concept that mes-
senger RNAs are polyadenylated transcripts and can be
converted, via the reverse transcription step, to cDNA
using a 30RACE adapter primer that binds the polyadeny-
lated tail (polyA) of the RNA. Certain noncoding RNAs are
polyadenylated while others are not, and the 30RACE
protocol (Ambion cat#AM1700) can only detect polyA
transcripts. RNA that is not polyadenylated cannot be
detected by this method.
Following reverse transcription, the cDNA is used in the
following amplification steps: a first round of PCR was
performed using the 30RACE Outer primer (provided by
the kit) and a gene-specific primer for the sense noncoding
RNA located 1 kb upstream of the TSS (Online Resource
4). An additional PCR step was performed using the
30RACE Inner primer and another gene specific primer.
Nested PCR DNA products were submitted for next gen-
eration sequencing.
Antisense oriented 30RACE
Total Human Brain RNA was reverse transcribed to cDNA
according to the manufacturer’s protocol as described
above for 30RACE-sense (Ambion cat#AM1700). The first
round of PCR was performed using primers located in
exon1, exon5 and exon17 in order to ensure coverage of the
entire locus. Nested PCR was performed using inner gene
specific primers located in the previously mentioned
regions (Online Resource 4). PCR products from all
regions of the locus were pooled and submitted for next
generation sequencing.
Next generation sequencing
The reads coming from sequencing of 50- and 30RACE
PCR products from Hiseq2000 sequencer were prepared
for Alignment by trimming the adapters from the
beginning and the end of the reads using PERL pro-
grams. Mapping of the reads coming from the sequenc-
ing of 50- and 30RACE PCR products was conducted
using version 2.0.1 of TopHat, using default settings for
Illumina reads. All reads were aligned to the hg19
assembly version (GRCh37) of the human genome and
the prebuilt index of the hg19 genome assembly (To-
pHat) was acquired from the TopHat homepage (http://
tophat.cbcb.umd.edu/).
Collection of tissue samples
19 human brain tissue samples were obtained from the
NICHD Brain and Tissue Bank for Developmental Disor-
ders at the University of Maryland, Baltimore, MD (Online
Resource 5). RNA was extracted from tissue using the
Trizol-Chloroform protocol and DNAse treated.
RNA from patient brain tissue and RNA from patient
blood
RNA from the cerebellum of 4 full mutation patients
(MIND1031-09LZ, MIND1031-08GP, MIND1033-08WS,
MINDJS-03) was provided courtesy of Dr. Tassone, UC
Davis, MIND Institute, CA. Detailed information about
patient’s samples can be found in Online Resource 5.
Blood from 2 control (616-11-ST, 378-11-JM), 2 pre-
mutation (288-12-JC, 453-12-EG) and 2 full mutation (22-
12-FD, 294-12-LP) patients was provided courtesy of Dr.
Tassone and it was processed to extract RNA (Tempus
tubes, Applied Biosystems) according to University of
California, Davis, Institutional Review Board-approved
human subject protocols.
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CDNA synthesis and quantitative PCR
The two novel transcripts, FMR5 and FMR6, were vali-
dated in several human brain regions. Strand specific
reverse transcription (RT) was performed on 200 ng of
commercial RNA (Clontech cat #636530, #636593,
#636535, #636563, #636564, #636526, #636570, #636561)
to make cDNA specific for FMR5 and FMR6. To rule out
DNA contamination in the RNA samples, we included a
‘‘No RT’’ condition, in which the reverse transcriptase
enzyme was omitted from the reaction. The primers used in
the RT are reported in Online Resource 6.
Quantitative PCR (qPCR) was used to compare the
expression of FMR5 and FMR6 in commercially available
RNA from several brain regions (Clontech), between
human brain specimens and lymphocytes from control,
premutation and full mutation individuals. FMR5 was
measured using a custom TaqMan probe while FMR4 and
FMR6 were quantified using SYBR Green, and the primers
used were validated by melting curve. Glucose-6-Phos-
phate Dehydrogenase and cyclophilin were used as
housekeeping genes for expression normalization. QPCR
data were analyzed by Delta Delta Ct method. Primers are
listed in Online Resource 6.
Results
The previous work reporting the presence of the antisense
lncRNAs called ASFMR1 and FMR4 was performed in
neuroblastoma (Khalil et al. 2008) and lymphoblastoid cell
lines (Ladd et al. 2007), which display different epigenetic
signatures than normal human brain potentially occluding
discovery of additional transcripts. Here we attempted to
identify novel transcripts derived from the FMR1 locus in
human brain from unaffected, FXS and FXTAS patients.
We screened the FMR1 locus for antisense transcripts by
combining rapid amplification of cDNA ends (RACE) with
next generation sequencing to determine the 50 and 30ends
of novel transcripts. This technique, also called Deep-
RACE, was also applied to search for sense-oriented
lncRNAs upstream of the transcription start site (TSS) of
FMR1. Sense oriented lncRNAs overlapping gene pro-
moters (Han et al. 2007; Kurokawa 2011; Martianov et al.
2007; Song et al. 2012) have been shown to regulate
transcription initiation (Martianov et al. 2007; Song et al.
2012) and may therefore contribute to FMR1 gene dys-
regulation in FXS/FXTAS.
We interrogated the entire FMR1 locus by performing
50- and 30RACE spanning four different regions: the FMR1
promoter (up to 1 kb from the TSS), exon 1, exon 5 and
exon 17. Our choice to explore these regions was based on
reported expressed sequence tags antisense to the FMR1
locus. We confirmed RACE-PCR amplification of novel
transcripts by capillary electrophoresis (Online Resource
1). These RACE PCR products were subjected to paired-
end sequencing on Illumina’s HiSeq2000 sequencer. This
procedure identified two novel noncoding RNAs, FMR5
(GenBank KC894604) and FMR6 (GenBank KC894603).
FMR5 is a sense-oriented, unspliced 800 nt long transcript
whose 50-end maps approximately 1 kb upstream of the
TSS of FMR1 (Fig. 1a, Online Resource 2). We were
unable to obtain 30RACE products for FMR5. One possible
reason is that the high GC content in the promoter and
50UTR of FMR1 interfered with the RACE reaction. FMR6
is a spliced 600 nt long antisense transcript whose
sequence is entirely complementary to the 30 region of
FMR1. It begins in the 30UTR and ends in exon 15 of
FMR1 (Fig. 1b, Online Resource 2). Interestingly,
sequencing reads for FMR6 align only to the exons of
FMR1, indicating that the transcript is spliced and that
FMR6 and FMR1 share the same splice junctions.
By definition, a noncoding RNA is a transcript that lacks
an open reading frame (ORF) and is therefore not translated.
Fig. 1 Alignment of Deep-RACE results to the FMR1 locus. The
reads obtained by Deep-RACE were visualized using the IGV
(Integrative Genomic Viewer) program after their alignment to the
human genome, and appear as grey bars above the schematic of the
FMR1 gene. a Those located in the promoter of FMR1 are the result
of the 50RACE, and represent a partial sequence of FMR5, the sense
transcript. b The reads that map to exon 15, exon 16, exon 17 and the
30UTR of FMR1 represent the antisense transcript, FMR6, and result
from 50 and 30 RACE deep sequencing
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In eukaryotes, protein-coding transcripts commonly contain
an ORF [300 nucleotides (100 amino acids). We used the
National Center for Biotechnology Information’s (NCBI’s)
‘‘ORF Finder’’ to determine ORFs in our two novel
transcripts. FMR6 was found to contain a few short ORFs
(*130 nt) (Online Resource 3). FMR5 contained a short
ORF of 114nt and one of 459 nt potentially encoding a
protein of 153 amino acids (Online Resource 3).
To explore the possibility that this hypothetical protein
is functional, we performed homology searches using the
NCBI tool BLASTP. This query detected no putative
conserved domains in any of the available databases (nr,
refseq_protein, swissprot, pat, pdb and env_nr). Lack of
homologous proteins and protein domains suggests that this
sequence is unlikely to encode a functional protein. As a
complementary strategy, we analyzed its potential domain
profile using the Conserved Domain Architecture Retrieval
Tool (Geer et al. 2002). This search also resulted in no hits,
further supporting the idea that the 459aa ORF does not
encode a functional protein.
We next assessed FMR5 and FMR6 expression in vari-
ous human brain regions. FMR5 and FMR6 expression was
detected at low levels in comparison to housekeeping genes
in adult human cerebellum, frontal and temporal lobes,
occipital and cerebral cortices and hippocampus, suggest-
ing their presence in most adult brain regions (Fig. 2). The
two transcripts were also expressed in fetal total brain RNA
(Fig. 2); however, we do not yet have evidence for a
developmental function of these transcripts.
Fig. 2 FMR5 and FMR6 are widely expressed in the human brain.
Expression of FMR5 (a) and FMR6 (b) was measured in RNA from
human cerebellum, cerebral cortex, occipital pole, frontal lobe,
temporal lobe, hippocampus and total fetal brain with qPCR. Data
were normalized to expression of the housekeeping gene, glucose-6-
phosphate dehydrogenase (G6PD). Error bars represent the standard
deviation of four technical replicates
Fig. 3 Expression of FMR5, FMR6, FMR1 and FMR4 in the brain
tissue of control, full mutation and premutation individuals. Expres-
sion of FMR5 (a), FMR6 (b), FMR1 (c) and FMR4 (d) was measured
in control, full mutation and premutation brain tissue by qPCR. Data
were normalized to expression of glucose-6-phosphate dehydrogenase
(G6PD), the housekeeping gene. In each panel, error bars for
individual patients represent the standard deviation of four technical
replicates. For mean expression values, error bars represent the
standard deviation within control, FM and PM groups. *p \ 0.05,
**p \ 0.01, NS not significant as determined by Student’s t test
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To explore the possibility that these novel transcripts
contribute to FXS pathogenesis, we assessed FMR5 and
FMR6 expression in post mortem brain tissue from full and
premutation individuals and unaffected controls. RNA
expression was quantified in tissue from 11 controls of
mixed gender, 7 male full mutation (FM) and 5 male
premutation (PM) individuals. On average, FMR5 expres-
sion did not differ significantly between full mutation,
premutation and control samples (Fig. 3a). However,
FMR6 expression was significantly decreased in both the
full mutation and premutation groups compared to controls,
with the exception of sample #NICHD1421, which
expresses FMR1 at levels similar to controls (Fig. 3b). All
other full mutation samples have, as expected, reduced
expression of FMR1 (Fig. 3c). We also determined
expression levels of FMR4, a lncRNA previously reported
by us (Khalil et al. 2008), in patient brain tissue. FMR4 was
not detectable in full mutation (FM) samples, and its
expression was increased in premutation (PM) samples
compared to controls (Fig. 3d). A no-RT negative control
was included in the detection of all ncRNA transcripts to
ensure that the signal was not accounted for by genomic
DNA contamination. The levels of FMR1, FMR4, FMR5
and FMR6 were variable in FXS and premutation brain
samples. It is likely that differences in the number of
repeats, extent of DNA methylation or extent of histone
modifications causes this variability. Variable expression
levels of these transcripts may translate into different
clinical outcomes. These lncRNAs may thus be useful as
biomarkers for FXS and FXTAS. To determine whether
lncRNA expression is linked to clinical phenotype, it is
necessary to measure these transcripts in a large cohort of
patients, and blood presents the most practical option for
both experimental and potential prognostic purposes.
To determine whether we can detect these novel lncR-
NAs in blood samples, we measured FMR4, FMR5 and
FMR6 expression in RNA extracted from peripheral blood
leukocytes in a limited number of patients (control n = 2,
premutation n = 2, full mutation n = 2) by strand-specific
reverse transcription quantitative PCR (RT-qPCR). All
control and PM samples demonstrated robust FMR1
expression; additionally, a moderate level of FMR1 mRNA
was detected in one of two FM patient samples, likely due
to mosaicism (Fig. 4a). Expression of FMR4, FMR5, and
FMR6 was also detectable in the majority of patient leu-
kocyte RNA samples albeit expression levels were lower
than those of FMR1 (Fig. 4b–d). These results establish the
feasibility of conducting studies correlating expression
levels of FMR4, FMR5, and FMR6 with clinical outcomes
in FXS and FXTAS patients.
Discussion
In recent years, the importance of lncRNAs in many
aspects of cell biology has received increasing attention
from the scientific community. For decades, these tran-
scripts were regarded as transcriptional noise, and thus
their role in many disease processes was overlooked.
Growing evidence points to a multitude of functions per-
formed by lncRNA, including regulation of transcription
and chromatin remodeling (Lee 2012). Here we report the
discovery of two novel transcripts that originate from the
FMR1 locus, adding complexity to a locus already known
to produce other lncRNAs (Khalil et al. 2008; Kumari and
Usdin 2010; Ladd et al. 2007) (Fig. 5).
The first lncRNA we report, FMR5, is a sense-oriented
transcript that overlaps the FMR1 promoter. The FMR5
transcription start site (TSS) is located 1 kb upstream of the
FMR1 TSS. FMR5 showed similar expression levels in
control, FM and PM brain tissue, suggesting that FMR5
transcription remains independent of chromatin modifica-
tions in FM and PM carriers. This is consistent with the
finding that in FXS repressive chromatin marks such as
Fig. 4 FMR1, FMR4, FMR5 and FMR6 are detectable in peripheral
blood leukocytes. Expression of FMR1 (a), FMR4 (b), FMR5 (c) and
FMR6 (d) RNA was measured in leukocytes from the peripheral
blood of control, full mutation and premutation individuals. Data
were normalized to the housekeeping gene cyclophilin (CYC). Error
bars represent the standard deviation of four technical replicates
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trimethylation of histone H3 at lysine 9 (H3K9me3) and
trimethylation of histone H4 at lysine 20 (H4K20me3)
associate with exon 1 of FMR1, which contains the CGG
repeats, but do not associate with the promoter region
(Kumari and Usdin 2010). On the other hand, levels of
three active chromatin marks, H3 acetylation (H3Ac), H4
acetylation (H4Ac) and H3K4 dimethylation (H3K4me2),
were reportedly lowered at the FMR1 promoter in FXS
(Gheldof et al. 2006). Furthermore, Kumari et al. (2010)
reported the presence of uncharacterized antisense lncR-
NAs in the FMR1 promoter of both normal and full
mutation cells, suggesting that the presence of repressive
histone marks in the FMR1 locus would not necessarily
inhibit the transcription of low abundance transcripts such
as FMR5.
FMR6 is a spliced antisense-oriented lncRNA that
overlaps exons 15-17 as well as the 30UTR of FMR1.
Unexpectedly, the splicing sites in FMR6 correspond
exactly to those of FMR1. Although very little is known
about the consensus sequences for splicing of noncoding
RNAs, it is possible that the reverse complement of the
canonical sites in FMR1 are being recognized as non-
canonical consensus sequences by the splicing machinery.
Programs such as ‘‘Human Splicing Finder’’ (http://www.
umd.be/HSF) can be used to predict non-canonical splicing
sites by incorporating matrices for auxiliary sequences
(Desmet et al. 2009). Further studies are required to
address this possibility.
Our data show that FMR6 expression is significantly
downregulated in FXS brain samples, as is expected due to
the reported decrease in H4Ac and H3K4me2 and increase
in H3K9me2 throughout the FMR1 locus, including the 30
region of FMR1 (Gheldof et al. 2006). However, DNA
methylation is restricted to the CGG repeat region at 50 end
of the gene. One full mutation case in our study,
NICHD#1421, displayed robust FMR1 expression in
addition to higher expression of FMR6 compared to other
FM patients. It is likely that in this case the 30UTR is
unaffected by the repressive chromatin modifications dis-
cussed above. Therefore it is possible that the observed
reduction in FMR6 expression is a consequence of histone
changes associated with the FM, rather than the DNA
methylation responsible for FMR1 silencing.
An unanticipated result is that FMR6 expression is
reduced in premutation-range samples; however, the
chromatin marks associated with the 30 end of FMR1 in
premutation carriers are yet to be described. As mentioned
previously, premutation-range expansions in the CGG
repeat region are reported to result in an open chromatin
state and increased FMR1 transcription (Tan et al. 2009).
Our data suggest that in addition, the premutation-range
CGG expansion somehow influences transcription or
chromatin state near the far-distal 30 end of the gene at the
premutation stage. Finally, we found that FMR4, similarly
to FMR1, is downregulated in brain from FM patients and
upregulated in PM carriers as we previously reported in
blood leukocytes (Khalil et al. 2008).
As discussed above, FMR5 and FMR6 have distinct
expression patterns, and additional studies are necessary to
clarify whether any potential regulatory function of each
transcript may contribute to FXS/FXTAS phenotypes.
FMR6 is complementary to the 30 region of FMR1 and may
therefore bind to the FMR1 mRNA, thereby regulating
FMR10s stability, splicing, subcellular localization and
translational efficiency. These regulatory functions have
been described for other lncRNAs (reviewed in (Faghihi
and Wahlestedt 2009)). For instance, stability of BACE1
mRNA is positively regulated by an antisense lncRNA to
BACE1 called BACE1AS (Faghihi et al. 2008). The possi-
bility that FMR6 regulates FMR1 mRNA splicing may be
relevant since extensive alternative splicing of FMR1 has
been demonstrated (Huang et al. 1996; Sittler et al. 1996).
Finally, as FMR6 overlaps two microRNA binding sites for
miR-19a and miR-19b in the 30UTR of FMR1 (Edbauer
et al. 2010), it is possible that this lncRNA can modulate
stability or translational efficiency of FMR1 through
interference with microRNA binding.
The fact that FMR1-derived lncRNAs are differentially
expressed in FXS and FXTAS suggests their usefulness as
biomarkers for these diseases. The use of lncRNAs as
biomarkers for human disease is a rather novel concept.
LncRNAs have emerged as novel diagnostic/prognostic
biomarkers in bodily fluid samples of cancer patients. One
example is the lncRNA prostate cancer antigen 3, which
can be detected in urine samples and has been shown to
improve diagnosis of prostate cancer (de Kok et al. 2002;
Reis and Verjovski-Almeida 2012). Investigating the
relationship between differential lncRNA expression and
clinical outcomes requires screening a large number of
patients with various degrees of defined FXS or FXTAS
symptoms. We have demonstrated through our six-patient
Fig. 5 The transcriptional landscape of the FMR1 gene locus is
complex. Graphical representation of the previously described and
newly reported lncRNAs expressed from the FMR1 locus. FMR5 is
transcribed from the FMR1 promoter in the sense direction, beginning
around 1 kb upstream from the FMR1 transcription start site. FMR6 is
an antisense-oriented lncRNA produced from the 30UTR of FMR1
Hum Genet (2014) 133:59–67 65
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pilot study that such a screening can be performed, as
FMR4, FMR5 and FMR6 are detectable in peripheral blood
leukocytes. If variability in expression of these transcripts
in FM and PM individuals correlates with clinical vari-
ability, it may be feasible to stratify FXS or FXTAS
patients for early intervention and improve clinical
outcomes.
In this study we used an innovative approach called
Deep-RACE, which combines RACE and next generation
sequencing (Olivarius et al. 2009) to identify novel tran-
scripts in high-throughput manner. This technique is highly
sensitive and enables detection of very low abundance
transcripts. Although our study uncovered two new lncR-
NAs, it is possible that we might have missed additional
FMR1-derived transcripts because the RACE reaction is
blocked by DNA sequences with high GC content, such as
found in the promoter and 50UTR of the FMR1 gene. While
there may well be other transcripts that are yet to be
identified, this report of two novel lncRNAs, FMR5 and
FMR6, further highlights the complexity of the FMR1
transcriptional landscape (Fig. 5). The functional proper-
ties of these lncRNAs remain to be explored. Should they
prove to be functional, we may begin to see Fragile X
Syndrome and its associated disorders as ‘‘single-locus’’
diseases in which multiple entities are affected by a repeat
expansion in a single gene.
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